Curated news and analysis on clinical trials, drug approvals, and medical research.
A Cleveland Clinic study found no racial survival disparities in multiple myeloma when patients have equal access to modern therapies. Clinical cases demonstrate long-term remission with second stem cell transplants and targeted agents like daratumumab.
Two new interchangeable Lucentis biosimilars — Lupin's Ranluspec and Formycon/Bioeq's Nufymco — have received FDA approval, while Xbrane's Lucamzi is under review with an October target date. The Lucentis global market was valued at $630 million in 2024.
The US is intensifying its response to New World screwworm as confirmed cases approach within 62 miles of the US-Mexico border. Emergency exemptions allow import of new treatments from Brazil, while sterile fly releases are expanded and a $100 million research initiative is launched. All southern ports of entry remain closed to livestock trade.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
AI-driven innovation is reshaping healthcare, biotech, and life sciences, as highlighted at the 2026 Forbes Iconoclast Summit. The Global Medical Tourism & Insurance Summit will convene in Palm Beach, Florida, in May to address cross-border care solutions. The life sciences sector enters 2026 with regulatory acceleration and AI embedded across the industry.
The FDA issued a new draft guidance on June 3, 2026, to update and replace its 2018 guidance on manufacturer-payor communications. It incorporates the PIE Act's statutory safe harbor for sharing information about investigational products with payors. The guidance creates a unified regulatory framework for both drugs and devices.
Long-term results from the phase III TRIANGLE trial show ibrutinib-based regimens improve survival in younger mantle cell lymphoma patients, while the ECHO trial establishes a new standard for older patients. Advances in CAR T-cell and bispecific antibody therapies are reshaping treatment for this rare blood cancer. The findings were presented at the annual MCL Consortium meeting.
Diabetes technology companies Dexcom, Insulet, and Sequel/Senseonics announced major product launches and algorithm updates. Dexcom is acquiring Nutrisense and launching an enhanced Stelo app, Insulet is rolling out an updated Omnipod 5 algorithm with lower glucose targets and Abbott compatibility, and Sequel/Senseonics have fully launched the Eversense 365 CGM with the twiist insulin delivery system in the U.S.
Scientists have developed a new transcriptomic clock that predicts biological age and mortality using gene activity patterns conserved across species. Longevity experts also recommend tracking specific biomarkers like fasting glucose, ApoB, and hs-CRP with optimal ranges to monitor health proactively. Regular biomarker testing from mid-30s onwards is encouraged for early detection of age-related changes.
Telix Pharmaceuticals reported full-year 2025 revenue of US$803.8 million, up 56% year-over-year, driven by strong growth in its Precision Medicine segment and the successful U.S. launch of Gozellix. The company issued 2026 revenue guidance of US$950-970 million and advanced multiple regulatory filings and late-stage pipeline programs.
Multiple market reports forecast the global biologics and antibody therapy markets will reach hundreds of billions of dollars by the 2030s, driven by monoclonal antibodies, biosimilar expansion, and targeted therapies.
iPSC-derived NK cell therapies are advancing rapidly with 12+ companies developing 15+ pipeline drugs. Japan's PMDA approved an iPS cell-derived NK cell therapy for mediastinal germ cell tumors in December 2025. Key clinical milestones include Century Therapeutics' CNTY-101 continuing in a Phase I/II trial.
South African authorities have executed multiple major drug enforcement operations, including a R250 million crystal meth lab bust in the North West and a network disruption in Gqeberha. These actions are part of an ongoing crackdown on organised drug crime.
The phase 3 RAMPART trial updated results show adjuvant durvalumab monotherapy did not significantly improve disease-free survival in resected renal cell carcinoma, while the durvalumab plus tremelimumab combination showed benefit in high-risk patients. Real-world treatment decisions are also shaped by patient-specific factors.
Two studies report on thoracic radiotherapy for lung cancer: a phase III trial found adding radiotherapy to chemoimmunotherapy did not improve survival in extensive-stage small cell lung cancer, while a retrospective review showed high local control rates with single-fraction 28 Gy stereotactic body radiotherapy.
Quantitative and functional MRI techniques are gaining traction as biomarkers in neurodegenerative diseases. A consensus statement provides MRI endpoint recommendations for clinical trials in hereditary ataxias like SCA and Friedreich ataxia. Separately, research shows resting-state fMRI can distinguish subtypes of multiple system atrophy and may improve early diagnosis.
Two separate studies examine interventions for individuals affected by preterm birth. A structured exercise program improved cardiovascular health and blood pressure in young adults born preterm. Meanwhile, prophylactic acetaminophen given to extremely preterm infants did not improve survival without severe morbidity, despite accelerating closure of a common heart defect.
A large international study published in eClinicalMedicine found that COVID-19 booster vaccination was tied to a 33% lower risk of preeclampsia in pregnant women across 18 countries. Getting COVID during pregnancy increased preeclampsia risk by 78% in unvaccinated women, but vaccination with a booster reduced those odds significantly.
Stanford Medicine Cancer Center is set to launch a first-of-its-kind compact proton therapy system this summer, offering precise tumor targeting with reduced side effects. In Kansas City, a multi-institution collaboration plans to establish one of the nation's first fully integrated theranostics platforms combining research, diagnostics, and targeted radiopharmaceutical treatments for both adults and children.
GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.
